Comparison between Humira vs Skyrizi
| Parameter | Humira | Skyrizi |
|---|---|---|
| Class | TNF inhibitor | IL-23 inhibitor |
| Mechanism | TNF blockade | IL-23 inhibition |
| Onset | Gradual | Gradual |
| Monitoring | None | None |
| Dosing | SC injection | SC injection |
| Half-life | ~2 weeks | ~28 days |
| Reversal Agent | None | None |
| Bleeding Risk | Infection risk | Infection risk |
| Indications | Autoimmune | Autoimmune |
| Renal Use | Caution | Caution |
| Pregnancy Use | Avoid | Avoid |
| Drug Interactions | Moderate | Moderate |
| Adherence Sensitivity | Moderate | Moderate |
| Best Use Case | Broad autoimmune | Psoriasis focused |
| Cost | High | High |
| Monitoring Burden | Low | Low |
| Clinical Flexibility | Moderate | Moderate |
| Real-world Convenience | Moderate | Moderate |
| Overall Verdict | Established | Targeted |
| Food Interactions | None | None |